Drug intelligence / Profile preview

Vildanef

Development stage: Unknown
Lead developer: Lloyd Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Vildanef is a branded generic formulation of vildagliptin, an oral anti-diabetic medication belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Marketed by Lloyd Healthcare in India, it is indicated for the management of type 2 diabetes mellitus. Vildagliptin works by inhibiting the DPP-4 enzyme, which normally degrades incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing this degradation, Vildanef increases the circulating levels of these hormones, thereby stimulating insulin secretion from pancreatic beta cells and reducing glucagon secretion from alpha cells in a glucose-dependent manner.

Brand names: Vildanef
Other names: vildagliptin

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on Vildanef.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vildanef.

Explore the full profile